Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2014-05-01 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2014
Regulatory Filings
2014-05-01 English
Earnings Release 2014
Earnings Release Classification · 100% confidence The document is titled "Company Announcement" and provides specific financial highlights for a single period ("Worldwide net sales of Arzerra® (ofatumumab) in Q1 2014 totaled GBP 15.6 million"). It details key figures (sales, expected royalty payment) immediately following the announcement date (April 30, 2014) and mentions the first quarter (Q1). This structure—a brief, immediate release of key performance indicators for a recent period—is characteristic of an Earnings Release (ER). It is too brief and focused on initial figures to be a comprehensive Interim Report (IR) or Annual Report (10-K). Since it is an initial announcement of results, ER is the most appropriate classification. Q1 2014
2014-04-30 English
Earnings Release 2014
Earnings Release Classification · 98% confidence The document is titled 'Selskabsmeddelelse' (Company Announcement) and reports specific financial figures ('Nettoomsætning for Arzerra i første kvartal 2014' - Net sales for Arzerra in the first quarter of 2014). It provides key highlights (GBP 15.6 million in net sales, expected royalty payment of DKK 28 million) immediately upon release, dated April 30, 2014. This format—a brief, immediate announcement of period results—is characteristic of an Earnings Release (ER), rather than the comprehensive Interim Report (IR) or the full Annual Report (10-K). The document length (4171 chars) is consistent with a brief release, not a full report. Q1 2014
2014-04-30 English
Regulatory Filings 2014
Regulatory Filings Classification · 100% confidence The document starts with "Selskabsmeddelelse" (Company Announcement) and details the FDA approval of a supplemental Biologics License Application (sBLA) for the drug Arzerra (ofatumumab) for a specific indication (previously untreated CLL patients). It includes clinical trial results (COMPLEMENT 1), safety information, and contact details for media/investors. This structure—a formal announcement of a significant regulatory/clinical event, often released to the public market immediately—is characteristic of a general regulatory announcement or press release, rather than a comprehensive periodic report (like 10-K or IR) or a specific financial filing. Since it is a formal announcement regarding a regulatory action (FDA approval) and is not a standard periodic report, the most appropriate classification is Regulatory Filings (RNS), which serves as a broad category for such official company news releases that don't fit other specific categories like ER or DIV.
2014-04-17 Danish
Earnings Release 2014
Earnings Release Classification · 99% confidence The document is a 'Company Announcement' dated April 17, 2014, from GlaxoSmithKline and Genmab regarding the FDA approval of Arzerra (ofatumumab) for a new indication in Chronic Lymphocytic Leukemia (CLL). It details clinical trial results (Phase III COMPLEMENT 1), safety information, and provides contact details for media and investors. This type of announcement, which communicates a significant regulatory event (FDA approval) and key clinical/safety data outside of a formal periodic report (like 10-K or IR), is best classified as an Earnings Release (ER) if it were quarterly results, but since it is a specific regulatory/product update announcement, it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate announcement, or potentially an Investor Presentation (IP) if it were structured as a deck, but it reads like a press release. Given the options, and that it is a direct announcement of a regulatory event and associated data, it is a general corporate/regulatory announcement. Since it is not a full report (10-K, IR) and not explicitly a management discussion (MDA) or earnings release (ER), the most appropriate general category for a press release announcing a major regulatory milestone is RNS (Regulatory Filings/General Announcement). However, because it contains substantial data and is clearly intended for investors/analysts, it strongly resembles an Earnings Release (ER) in format (announcing key results/updates), even though it's not strictly quarterly earnings. Given the context of pharmaceutical announcements, these press releases often fall under ER or RNS. Since it is a major announcement of a product milestone, ER is often used for significant news releases. Let's re-evaluate: It is not an earnings release (no revenue/EPS figures). It is a press release announcing FDA approval and Phase III data. This is a core regulatory/investor communication. RNS is the fallback for miscellaneous regulatory announcements. Given the specific nature of the announcement (FDA approval), RNS is the most fitting general regulatory category. Q2 2014
2014-04-17 English
AGM Information 2014
AGM Information Classification · 99% confidence The document is titled 'Company Announcement' and explicitly states it follows the 'Annual General Meeting held on April 9, 2014'. The content details subsequent actions by the Board of Directors, specifically the constitution of the board and the decision to issue 8,000 warrants to employees. While it mentions the AGM, the primary focus is the corporate action (warrant issuance) taken immediately after the meeting, which relates to capital structure changes and employee compensation/incentives. Since the document is a general announcement following a meeting and details a specific corporate action (warrant issuance), it fits best under Capital/Financing Update (CAP) or potentially Share Issue/Capital Change (SHA). However, the issuance of warrants is a financing/capital structure activity. Given the context of the warrant issuance details (exercise price, vesting, Black-Scholes valuation), 'Capital/Financing Update' (CAP) is the most appropriate classification for this specific corporate action announcement.
2014-04-09 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.